Drw Securities, LLC Affimed N.V. Transaction History

Drw Securities, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.05 - $4.34 $349,225 - $496,930	-114,500 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.82 - $4.67 $245,622 - $406,757	87,100 Added 317.88%	114,500 $356,000
Q3 2018 Nov 14, 2018	SELL	$1.45 - $6.15 $134,270 - $569,490	-92,600 Reduced 77.17%	27,400 $119,000
Q2 2018 Aug 14, 2018	BUY	$1.65 - $2.5 $16,500 - $25,000	10,000 Added 9.09%	120,000 $198,000
Q1 2018 May 14, 2018	BUY	$1.25 - $2.65 $137,500 - $291,500	110,000 New	110,000 $204,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $391M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Drw Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Drw Securities, LLC with notifications on news.